Safety and Efficacy of Apixaban in the Treatment of Atrial Fibrillation

Safety and Efficacy of Apixaban in the Treatment of Atrial Fibrillation

Show other versions (1)

Bibliographic Details
Main Authors:	Andrew Martin, Ralph Stewart
Format:	Article
Language:	English
Published:	SAGE Publishing 2012-07-01
Series:	Clinical Medicine Insights: Cardiology
Online Access:	http://la-press.com/safety-and-efficacy-of-apixaban-in-the-treatment-of-atrial-fibrillatio-a3265

Similar Items

Safety and Efficacy of Apixaban in the Treatment of Atrial Fibrillation
by: Andrew Martin, et al.
Published: (2012-01-01)

Use, Persistence, Efficacy, and Safety of Apixaban in Patients with Non-Valvular Atrial Fibrillation in Unselected Patients in Germany. Results of the Prospective Apixaban in Atrial Fibrillation (APAF) Registry
by: Uwe Zeymer, et al.
Published: (2020-07-01)

Balance of efficacy and safety in the prevention of stroke in patients with non-valvular atrial fibrillation: potential of apixaban. Questions and answers
by: I. S. Yavelov
Published: (2015-12-01)

Clinical experience with apixaban in atrial fibrillation: implications of AVERROES
by: De Caterina R
Published: (2011-07-01)

Apixaban in non-valvular atrial fibrillation and treatment of venous thromboembolism: universal safety advantage in different categories of patients
by: I. S. Yavelov
Published: (2020-10-01)

Non-valvular atrial fibrillation: impact of apixaban on patient outcomes
by: Ioannou A, et al.
Published: (2017-11-01)

Development of Pacemaker Lead Thrombosis in a Patient with Atrial Fibrillation during Apixaban Treatment
by: Adem Adar, et al.
Published: (2019-10-01)

Cost-effectiveness of Apixaban for Stroke Prevention in Patients with Atrial Fibrillation in Algeria
by: Yazid Aoudia, et al.

Cost-effectiveness of apixaban compared with warfarin for stroke prevention in atrial fibrillation.
by: Soyon Lee, et al.
Published: (2012-01-01)

PHARMACOECONOMIC ASPECTS OF APIXABAN FOR PREVENTION OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION
by: A. V. Rudakova
Published: (2015-09-01)

PHARMACOECONOMIC ASPECTS OF APIXABAN FOR PREVENTION OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION
by: A. V. Rudakova
Published: (2015-09-01)

Economic evaluation of apixaban for the prevention of stroke in non-valvular atrial fibrillation in the Netherlands.
by: Jelena Stevanović, et al.
Published: (2014-01-01)

Spontaneous Spinal Epidural Hematoma in a Patient on Apixaban for Nonvalvular Atrial Fibrillation
by: Ahmad El Alayli, et al.
Published: (2020-01-01)

Secondary prevention of stroke in atrial fibrillation, use of apixaban: ARISTOTLE, AVERROES studies
by: V.A. Parfenov, et al.
Published: (2014-10-01)

Safety and Efficacy of Dronedarone in the Treatment of Atrial Fibrillation/Flutter
by: Gerald V. Naccarelli, et al.
Published: (2011-01-01)

Safety and Efficacy of Dronedarone in the Treatment of Atrial Fibrillation/Flutter
by: Gerald V. Naccarelli, et al.
Published: (2011-10-01)

Apixaban concentration variability and relation to clinical outcomes in real-life patients with atrial fibrillation
by: Alenka Mavri, et al.
Published: (2021-07-01)

Comparison of peri-procedural anticoagulation with rivaroxaban and apixaban during radiofrequency ablation of atrial fibrillation
by: Jayasree Pillarisetti, et al.
Published: (2020-11-01)

Cost-effectiveness of apixaban for stroke prevention in non-valvular atrial fibrillation in Saudi Arabia
by: Ahmad S. Hersi, et al.
Published: (2019-07-01)

The influence of residual apixaban on bleeding complications during and after catheter ablation of atrial fibrillation
by: Yutaro Mukai, et al.
Published: (2017-10-01)

CLINICAL AND ECONOMICAL COMPARISON OF RIVAROXABAN AND APIXABAN USE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
by: S. V. Nedogoda, et al.
Published: (2017-03-01)

Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for the Prevention of Stroke Prophylaxis in Atrial Fibrillation
by: Harrington, Amanda Rose
Published: (2012)

Safety and Efficacy of Apixaban versus warfarin in patients with atrial fibrillation or Venous Thromboembolism and End-Stage renal disease on hemodialysis: A systematic review and meta-analysis
by: Ghulam Murtaza, et al.
Published: (2021-07-01)

Efficacy and safety of radiofrequency catheter ablation in the treatment of atrial fibrillation
by: Hakalahti, A. (Antti)
Published: (2015)

Safety and effectiveness of apixaban in Japanese patients with nonvalvular atrial fibrillation in clinical practice: A regulatory postmarketing surveillance, the STANDARD study
by: Hiroshi Inoue, et al.
Published: (2019-06-01)

Single low-dose of apixaban in patients with atrial fibrillation after transcatheter aortic valve implantation
by: Gabriela Veiga-Fernández, et al.
Published: (2020-08-01)

Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings.
by: Lisa A de Jong, et al.
Published: (2019-01-01)

Budget impact analysis of apixaban versus other NOACs for the prevention of stroke in Italian atrial fibrillation patients
by: Lorenzo Pradelli, et al.
Published: (2014-12-01)

Cost‑effectiveness analysis of apixaban versus other NOACs for the prevention of stroke in Italian atrial fibrillation patients
by: Lorenzo Pradelli, et al.
Published: (2014-12-01)

Patient satisfaction after switching from warfarin to apixaban in patients with nonvalvular atrial fibrillation: AGAIN study
by: Koretsune Y, et al.
Published: (2017-12-01)

Comparative pharmacoeconomic assessment of apixaban vs. standard of care for the prevention of stroke in Italian atrial fibrillation patients
by: Lorenzo Pradelli, et al.
Published: (2014-12-01)

Transcatheter Heart Valve Thrombosis in a Patient With Polycythemia Vera Despite Apixaban Therapy for Atrial Fibrillation
by: Gauranga Mahalwar, MD, et al.
Published: (2021-02-01)

Short-Term Apixaban for Documented Left Atrial Appendage Thrombus in High-Risk Atrial Fibrillation Patients Undergoing Left Atrial Appendage Occlusion
by: Wern Yew Ding, et al.
Published: (2020-10-01)

APPROACHES TO THE CHOICE OF ANTICOAGULANT THERAPY IN THE TREATMENT OF PATIENTS WITH COMBINATION OF ATRIAL FIBRILLATION WITH CORONARY HEART DISEASE OR PERIPHERAL ATHEROSCLEROSIS: POTENTIAL OF APIXABAN
by: O. D. Ostroumova, et al.
Published: (2018-07-01)

A prospective multicenter study of direct comparison of feasibility and safety of pulmonary vein isolation using the minimally interrupted apixaban between second‐generation cryoballoon and radiofrequency ablation of paroxysmal atrial fibrillation: J‐HIT apixaban
by: Atsuhiko Yagishita, et al.
Published: (2020-08-01)

The safety and efficacy of hybrid ablation for the treatment of atrial fibrillation: A meta-analysis.
by: Yun-Qiu Jiang, et al.
Published: (2018-01-01)

Successful resolution with apixaban of a massive left atrial appendage thrombus due to nonrheumatic atrial fibrillation: A case report and review
by: Bader Abu Ghalyoun, et al.
Published: (2018-01-01)

Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: A nationwide pharmacoepidemiological study.
by: Lars J Kjerpeseth, et al.
Published: (2019-01-01)

Real-World Analysis of Potential Pharmacokinetic and Pharmacodynamic Drug Interactions with Apixaban in Patients with Non-Valvular Atrial Fibrillation
by: Badreldin HA, et al.
Published: (2020-07-01)

Apixaban in a Morbid Obese Patient with Atrial Fibrillation: A Clinical Experience Using the Plasmatic Drug Evaluation
by: Russo V, et al.
Published: (2020-03-01)